Lung Cancer Surgery after Neoadjuvant Immunotherapy

Lung Cancer Surgery after Neoadjuvant Immunotherapy

In early-stage lung cancer, recurrences are observed even after curative resection. Neoadjuvant immunotherapy might be a promising approach to eliminate micrometastasis and to potentially reduce recurrence rates and improve survival. Early trials have shown encouraging rates of pathologic response t...

Full description

Bibliographic Details
Main Authors: Dirk Stefani, Till Plönes, Jan Viehof, Kaid Darwiche, Martin Stuschke, Martin Schuler, Clemens Aigner
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
lung cancer surgery
neoadjuvant immunotherapy
Online Access:https://www.mdpi.com/2072-6694/13/16/4033
id doaj-6434b6322077444c9ac96d2cd6cf4b45
record_format Article
spelling doaj-6434b6322077444c9ac96d2cd6cf4b452021-08-26T13:35:34ZengMDPI AGCancers2072-66942021-08-01134033403310.3390/cancers13164033Lung Cancer Surgery after Neoadjuvant ImmunotherapyDirk Stefani0Till Plönes1Jan Viehof2Kaid Darwiche3Martin Stuschke4Martin Schuler5Clemens Aigner6Department of Thoracic Surgery, University Medicine Essen–Ruhrlandklinik, Tueschener Weg 40, 45239 Essen, GermanyDepartment of Thoracic Surgery, University Medicine Essen–Ruhrlandklinik, Tueschener Weg 40, 45239 Essen, GermanyDepartment of Thoracic Surgery, University Medicine Essen–Ruhrlandklinik, Tueschener Weg 40, 45239 Essen, GermanyDepartment of Pneumology, University Medicine Essen–Ruhrlandklinik, Tueschener Weg 40, 45239 Essen, GermanyDepartment of Radiation Oncology, University Medicine Essen, Hufelandstrasse 55, 45147 Essen, GermanyDepartment of Medical Oncology, University Medicine Essen, Hufelandstrasse 55, 45147 Essen, GermanyDepartment of Thoracic Surgery, University Medicine Essen–Ruhrlandklinik, Tueschener Weg 40, 45239 Essen, GermanyIn early-stage lung cancer, recurrences are observed even after curative resection. Neoadjuvant immunotherapy might be a promising approach to eliminate micrometastasis and to potentially reduce recurrence rates and improve survival. Early trials have shown encouraging rates of pathologic response to neoadjuvant therapy and have demonstrated that surgery can be safely performed after neoadjuvant immunotherapy with various agents and in combination with chemo-(radio)therapy. However, whether these response rates translate into improved disease-free survival rates and overall survival rates remains to be determined by ongoing phase III studies.https://www.mdpi.com/2072-6694/13/16/4033lung cancer surgeryneoadjuvant immunotherapy
collection DOAJ
language English
format Article
sources DOAJ
author Dirk Stefani
Till Plönes
Jan Viehof
Kaid Darwiche
Martin Stuschke
Martin Schuler
Clemens Aigner
spellingShingle Dirk Stefani
Till Plönes
Jan Viehof
Kaid Darwiche
Martin Stuschke
Martin Schuler
Clemens Aigner
Lung Cancer Surgery after Neoadjuvant Immunotherapy
Cancers
lung cancer surgery
neoadjuvant immunotherapy
author_facet Dirk Stefani
Till Plönes
Jan Viehof
Kaid Darwiche
Martin Stuschke
Martin Schuler
Clemens Aigner
author_sort Dirk Stefani
title Lung Cancer Surgery after Neoadjuvant Immunotherapy
title_short Lung Cancer Surgery after Neoadjuvant Immunotherapy
title_full Lung Cancer Surgery after Neoadjuvant Immunotherapy
title_fullStr Lung Cancer Surgery after Neoadjuvant Immunotherapy
title_full_unstemmed Lung Cancer Surgery after Neoadjuvant Immunotherapy
title_sort lung cancer surgery after neoadjuvant immunotherapy
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2021-08-01
description In early-stage lung cancer, recurrences are observed even after curative resection. Neoadjuvant immunotherapy might be a promising approach to eliminate micrometastasis and to potentially reduce recurrence rates and improve survival. Early trials have shown encouraging rates of pathologic response to neoadjuvant therapy and have demonstrated that surgery can be safely performed after neoadjuvant immunotherapy with various agents and in combination with chemo-(radio)therapy. However, whether these response rates translate into improved disease-free survival rates and overall survival rates remains to be determined by ongoing phase III studies.
topic lung cancer surgery
neoadjuvant immunotherapy
url https://www.mdpi.com/2072-6694/13/16/4033
work_keys_str_mv AT dirkstefani lungcancersurgeryafterneoadjuvantimmunotherapy
AT tillplones lungcancersurgeryafterneoadjuvantimmunotherapy
AT janviehof lungcancersurgeryafterneoadjuvantimmunotherapy
AT kaiddarwiche lungcancersurgeryafterneoadjuvantimmunotherapy
AT martinstuschke lungcancersurgeryafterneoadjuvantimmunotherapy
AT martinschuler lungcancersurgeryafterneoadjuvantimmunotherapy
AT clemensaigner lungcancersurgeryafterneoadjuvantimmunotherapy
_version_ 1721194479496462336

Similar Items